Search company, investor...
Search

Predict your next investment

Capital Cell company logo
Equity Crowdfunding
INTERNET | E-Commerce / Marketplace
capitalcell.es

See what CB Insights has to offer

Investments

43

Portfolio Exits

1

Partners & Customers

1

About Capital Cell

Capital Cell is a pan-European crowdfunding platform for biotech and Life Sciences companies. Using this collective financing system, entrepreneurs can obtain the funds they need for their companies from private investors around the world.

Capital Cell Headquarters Location

Oficina 2D2 Plaça de Pau Vila, 1

Barcelona, 08039,

Spain

+(34) 931004287

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Capital Cell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Capital Cell in 2 Expert Collections, including Digital Health.

D

Digital Health

13,112 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

F

Fintech

4,872 items

Track and capture company information and workflow.

Capital Cell Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Capital Cell Rank

Latest Capital Cell News

Laminar Pharma Seeks €30 Million to Quell Glioblastoma

May 24, 2022

Of the total amount that Laminar Pharma estimates it needs, $10.7 million (€10 million) correspond to bank financing already agreed with Banca March. In addition, the company has just opened a round with Capital Cell. The majority of the resources raised by the company will be dedicated to the clinical study of LAM561 and the rest will go to various preclinical and clinical studies 0 Laminar Pharma is in search of financing , to develop its drug against brain tumors. The Balearic company specialized in the rational design of drugs needs $32 million (€30 million) to be able to carry out clinical studies of its product LAM561, indicated against glioblastoma, an aggressive type of cancer that is generated in the brain or spinal cord. This was recognized by Pablo Escribá, CEO and founder of Laminar Pharma, to PlantaDoce, which wants to launch this product on the market at the end of 2023 or the beginning of 2024. Of the total amount that Laminar Pharma estimates it needs, $10.7 million (€10 million) correspond to bank financing already agreed with Banca March, according to the company’s founder. Regarding the other $21.4 million (€20 million), the company has already made a move and has just opened a financing round of $1.7 million (€1.6 million) through the crowdfunding platform Capital Cell, with which it has so far raised around $750,000 (€700,000) with the participation of more than one hundred investors. In 2019, Laminar Pharma closed its first round via Capital Cell raising $2.14 million (€2 million). Read more about Laminar Pharma and find the most important financial news of the day with the Born2Invest mobile app. Laminar Pharma is confident of launching its drug against glioblastoma by 2024 at the latest The majority of the resources raised by the company will be dedicated to the clinical study of LAM561 and the rest will go to various preclinical and clinical studies with investigational drugs in Laminar Pharma’s portfolio. Laminar Pharma is a company working on the design of innovative drugs based on a proprietary technology platform called membrane lipid therapy (melitherapy). Most drugs are directed towards proteins or nucleic acids, but until now no therapies have been directed towards the other large group of macromolecules, the lipids that make up cell membranes. Since 2006, the company has been researching the lipid alterations that occur in the cell membrane, studying their relationship with various pathological processes and developing pioneering and innovative therapeutic molecules to improve the quality of life of people affected by serious diseases. LAM561 is currently in clinical phase III LAM561 is currently in clinical phase III and is expected to apply for marketing approval within a year. The clinical trial aims to make LAM561 the first-line and standard of care treatment for glioblastoma. The company is 80% owned by a group of fifteen to twenty shareholders, including the founder of Laminar Pharma. Pablo Escribá invented and developed melitherapy and is the co-inventor of the patents under development by Laminar Pharma and its licensees. In addition, he has conducted research studies in the United States (New York, Kansas City, and Charleston), Switzerland, and Hungary. Another of the company’s shareholders is the Matutes family. In fact, the board of Laminar Pharma includes Manuel Matutes Mestre, founding partner of Aguaduna.com, Kei Cities, and director of the Palladium Hotel group. __ DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our  disclaimer  for more information. This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these  important disclosures . First published in  PlantaDoce , a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail. Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Capital Cell Investments

43 Investments

Capital Cell has made 43 investments. Their latest investment was in RIMBARLAT as part of their Angel on October 10, 2022.

CBI Logo

Capital Cell Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/3/2022

Angel

RIMBARLAT

$0.6M

Yes

1

6/21/2022

Seed VC - II

ADmit Therapeutics

$4.42M

Yes

1

5/31/2022

Angel - II

VB Devices

$1.07M

No

2

4/30/2022

Angel

Subscribe to see more

$99M

Subscribe to see more

10

4/27/2022

Angel

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/3/2022

6/21/2022

5/31/2022

4/30/2022

4/27/2022

Round

Angel

Seed VC - II

Angel - II

Angel

Angel

Company

RIMBARLAT

ADmit Therapeutics

VB Devices

Subscribe to see more

Subscribe to see more

Amount

$0.6M

$4.42M

$1.07M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Capital Cell Portfolio Exits

1 Portfolio Exit

Capital Cell has 1 portfolio exit. Their latest portfolio exit was methinks on June 22, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2022

Acquired

$99M

2

Date

6/22/2022

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

2

Capital Cell Partners & Customers

1 Partners and customers

Capital Cell has 1 strategic partners and customers. Capital Cell recently partnered with aescuvest on January 1, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

1/1/2021

Partner

Germany

Date

1/1/2021

Type

Partner

Business Partner

Country

Germany

News Snippet

Sources

Capital Cell Team

3 Team Members

Capital Cell has 3 team members, including current Founder, Chief Executive Officer, Nigel Ten Fleming.

Name

Work History

Title

Status

Nigel Ten Fleming

Founder, Chief Executive Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Nigel Ten Fleming

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Chief Executive Officer

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.